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Symptoms in late-onset neuromuscular disorders initiate only from midlife onward and
progress with age. These disorders are primarily determined by identified hereditable
mutations, but their late-onset symptom manifestation is not fully understood. Here, we
review recent research developments on the late-onset autosomal dominant oculopharyn-
geal muscular dystrophy (OPMD). OPMD is caused by an expansion mutation in the gene
encoding for poly-adenylate RNA binding protein1 (PABPN1). The molecular pathogenesis
for the disease is still poorly understood. Despite a ubiquitous expression of PABPN1,
symptoms in OPMD are limited to skeletal muscles. We discuss recent studies showing
that PABPN1 levels in skeletal muscles are lower compared with other tissues, and specif-
ically in skeletal muscles, PABPN1 expression declines from midlife onward. In OPMD,
aggregation of expanded PABPN1 causes an additional decline in the level of the functional
protein, which is associated with severe muscle weakness in OPMD. Reduced PABNPN1
expression in muscle cell culture causes myogenic defects, suggesting that PABPN1 loss-
of-function causes muscle weakness in OPMD and in the elderly. Molecular signatures of
OPMD muscles are similar to those of normal muscle aging, although expression trends
progress faster in OPMD. We discuss a working hypothesis that aging-associated factors
trigger late-onset symptoms in OPMD, and contribute to accelerated muscle weakness in
OPMD.We focus on the pharyngeal and eyelid muscles, which are often affected in OPMD
patients. We suggest that muscle weakness in OPMD is a paradigm for muscle aging.
Keywords: adult myopathy, muscle degeneration, OPMD, PABPN1, RNA metabolism
In aging populations, late-onset disorders are highly common,
among which late-onset neuromuscular (NM) disorders are a
subset. NM disorders affect muscle fibers and/or the central and
peripheral nervous system and the NM junction that control the
muscle fibers. At present, these disorders are often incurable. As
life expectancy rises, the prevalence of late-onset disorders caus-
ing chronic muscle weakness increases. Muscle symptoms can
manifest from midlife onward, leading to a drastic functional
decline with social and economic burdens. This suggests that
in addition to the fundamental genetic defect(s), possible simi-
lar aging-associated regulators trigger the late onset of symptoms
and progression thereof. For example, protein catabolism, which
discards defective or redundant proteins (mainly through the
ubiquitin proteasome and autophagy systems), has been impli-
cated as a predominant regulator in normal aging and late-onset
diseases [reviewed in Low (2011) and Bonaldo and Sandri (2013)].
Reduced protein catabolism can also lead to an accumulation of
aggregation-prone proteins and formation of insoluble protein
aggregates. These aggregates are often the pathological hallmark
in a number of late-onset neurological and/or muscular disor-
ders (Ruegg and Glass, 2011; Bonaldo and Sandri, 2013). Although
symptoms of these diseases widely vary, symptoms often initiate in
a small subset of muscular or neuronal tissues (Ross and Poirier,
2005). While the primary genetic causes for these disorders are
known, why symptoms initiate from midlife onward in specific
tissues and how symptoms progress with age is still obscure.
Oculopharyngeal muscular dystrophy (OPMD) is an autoso-
mal dominant and rare myopathy. The estimated prevalence in
Western countries is 1:100,000 [reviewed in Raz et al. (2013)].
Due to founder effects, clusters with a higher prevalence are found
in French-Canadians and in the Bukhara community in Israel
(1:1000 and 1:600, respectively) (Blumen et al., 2000; Laberge
et al., 2005). It has been suggested, however, that outside these
communities, the disease remains underdiagnosed (Ruegg et al.,
2005). In OPMD, skeletal muscles are predominantly affected,
whereby initial symptoms are manifested in only a subset of mus-
cles. Most commonly, this leads to lowering (ptosis) of the eyelids
and swallowing difficulties (dysphagia). With disease progression,
additional skeletal muscles can be affected including the proxi-
mal muscles of the lower limb (including the quadriceps muscles)
(Fischmann et al., 2012). OPMD is a monogenic disorder and its
etiology is found in an alanine expansion mutation in the gene
encoding for poly-adenylate (poly(A)) binding protein nuclear 1
(PABPN1) (Brais et al., 1998). Formation of insoluble inclusions
in the cell nucleus is the pathological hallmark of OPMD muscles
(Tome and Fardeau, 1980). Under physiological expression levels,
expanded (exp)PABPN1 is more prone to aggregation compared
with the wild-type PABPN1 (Raz et al., 2011a). High overexpres-
sion of expPABPN1 in muscles of various animal models causes
muscle weakness, and it is suggested that accumulation of aggre-
gates could be the cause for the muscle dysfunction (Davies et al.,
2005). High overexpression of expPAPBN1 in animal models, as
Frontiers in Aging Neuroscience www.frontiersin.org November 2014 | Volume 6 | Article 317 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Raz and Raz OPMD as a paradigm for sarcopenia
well as in cellular models leads to cell death, suggesting that exp-
PABPN1 aggregates are toxic (Davies et al., 2008). Importantly,
treatments that may reduce aggregation lead to less cell death and
reduced muscle weakness in these animal models (Davies et al.,
2006, 2010; Catoire et al., 2008; Chartier et al., 2009). Based on
those models, it was suggested that muscle symptoms in OPMD
are caused by a PABPN1 gain-of-function. However, it is not
resolved whether animal models with high overexpression in mus-
cles are relevant to OPMD. For example, high overexpression of
expPABPN1 was not reported in OPMD heterozygous patients.
Moreover, aggregates of wild-type PABPN1 were found in unaf-
fected rat neural cells (Berciano et al., 2004). Altogether, it is
striking that despite the well-known genetic cause for OPMD, the
molecular mechanisms and physiological conditions that lead to
muscle symptoms are poorly understood. Here, we discuss four
questions for OPMD pathophysiology.
IS OPMD AN RNA METABOLISM DISORDER?
Poly-adenylate RNA binding protein1 is multifunctional regulator
of RNA metabolism. Initially, it was identified in vitro as a regu-
lator of poly(A) tail length (Kerwitz et al., 2003), subsequently
was validated in vivo (Benoit et al., 2005), and more recently, it
was shown to have an impact on mRNA decay (Bresson and Con-
rad, 2013). PABPN1 knockdown in mouse muscle cells causes
reduced poly(A) tail length that is associated with myogenesis
defects (Apponi et al., 2010); however, the relevance for OPMD
and muscle aging is unsettled. A change in poly(A) tail length
was not found in muscles from OPMD patients (Calado et al.,
2000). Recent studies revealed additional molecular functions for
PABPN1. A genome-wide shift from distal to proximal alterna-
tive polyadenylation site (PAS) and accumulation of shortened
transcripts were found in the mouse model for OPMD, A17.1,
which was generated by expPABPN1 overexpression in muscles,
and in cells with reduced PABPN1 expression (de Klerk et al.,
2012; Jenal et al., 2012). Similar alternative PAS utilization was
found in models with expPABPN1 overexpression and PABPN1
downregulation, suggesting that PABPN1 loss-of-function causes
defects in RNA metabolism (de Klerk et al., 2012; Jenal et al.,
2012). In OPMD muscles, PABPN1 downregulation was found
to be comparable to age-matching controls (Anvar et al., 2013).
Reduced PABPN1 levels in cellular models cause myogenic defects
(Apponi et al., 2010; Anvar et al., 2013). In addition, PABPN1 was
also found to regulate long non-coding RNA expression (Beaulieu
et al., 2012). However, so far, alternative PAS or long non-coding
RNA expression was not reported in OPMD patient muscles. To
adequately understand how PABPN1 regulates changes in RNA
metabolism in OPMD with an impact on muscle weakness, exper-
iments should be conducted in models with physiological levels of
PABPN1.
Aberrant RNA metabolism is not specific to OPMD, but is
found in a wide spectrum of unrelated late-onset neurologi-
cal and/or muscular disorders (O’Rourke and Swanson, 2009;
Anthony and Gallo, 2010). Since these disorders share a late
onset of symptoms and progression with age, age-associated reg-
ulators of RNA metabolism could be affected. It is still unclear
whether similar regulators of RNA metabolism are affected in these
disorders. In OPMD, affected muscles as well as muscles from
pre-symptomatic family members can be accessible for research
(Fischmann et al., 2012; Anvar et al., 2013). Therefore, OPMD
could be used as a paradigm to study the functional contribu-
tion of RNA metabolism to symptoms in late-onset neurological
and/or muscular disorders and to study a possible regulatory role
in the age-associated progression of the symptoms.
WHY ARE SKELETAL MUSCLES PRIMARILY AFFECTED
IN OPMD?
Poly-adenylate RNA binding protein1 is essential for cell vitality
(Bhattacharjee and Bag, 2012) and is expressed in all cells; how-
ever symptoms are predominantly manifested in skeletal muscles.
In OPMD patients, PABPN1 expression is specifically reduced in
affected Vastus lateralis muscles, while PABPN1 levels in whole
blood are unchanged between OPMD patients and healthy con-
trols (Anvar et al., 2013). In Dutch and Danish OPMD patients,
weakness of the quadriceps muscles is reported as one of the ini-
tial symptoms (Sluijs et al., 2003; Witting et al., 2014). PAPBN1
level is lower in skeletal muscles of both human being and mouse,
compared with a spectrum of tissues (Apponi et al., 2013). Since
symptoms in OPMD are predominant in skeletal muscles, this
suggests that below a certain crucial level, a functional impact is
manifested. Although a threshold for functional PABPN1 is yet to
be defined, due to low PABPN1 expression levels in skeletal mus-
cles (Apponi et al., 2013) this crucial level could reach a functional
impact. In other tissues, however, PABPN1 levels are sufficiently
high (Apponi et al., 2013), and thus, if any aging-associated decline
may occur (Anvar et al., 2013), they would be spared from a func-
tional deficiency (Figure 2). Indeed, altered PABPN1 at 40, 60,
or 80% expression level causes reciprocal decrease in the expres-
sion of sarcomeric genes (Anvar et al., 2013). This working model
requires additional in vivo experiments.
It is not fully understood why levels of PABPN1 are lower in
skeletal muscles. PABPN1 mRNA is less stable in muscles com-
pared with other tissues (Apponi et al., 2013). PABPN1 mRNA
binds to PABPN1 protein (Raz et al., 2014), which potentially
affects PABPN1 mRNA stability, nuclear export, and transla-
tion (Figure 1). As yet, regulators of mRNA stability in muscles
and aging-associated changes are poorly understood. In addi-
tion, PABPN1 protein turnover is regulated by the ubiquitin
proteasome system (UPS) (Raz et al., 2011b). Differences in poly-
ubiquitination levels between wild type and expPABPN1 result in
higher protein turnover of wild-type PAPBN1 as compared with
expPABPN1 (Raz et al., 2011b). Since PABPN1 is prone to aggre-
gation, higher protein accumulation leads to aggregate formation
and reduced availability of the functional protein. PABPN1 pro-
tein accumulation is regulated by ARIH2 E3-ligase, whose level
also declines from midlife onward in skeletal muscles (Raz et al.,
2014). In OPMD muscles, ARIH2 level is lower compared to age-
matching controls, which in part could result by the alternative
PAS utilization in ARIH2 3′-UTR that is directly regulated by
PABPN1 level. In addition, as ARIH2 protein is entrapped in exp-
PABPN1 aggregates, functional protein levels would be depleted
(Raz et al., 2014). Protein entrapment in PABPN1 aggregates was
reported for other E3 ligases and the proteasome (Corbeil-Girard
et al., 2005; Tavanez et al., 2005; Anvar et al., 2011), suggest-
ing that the UPS machinery is dysregulated in OPMD. In turn,
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FIGURE 1 | A schematic working model for regulation of PABPN1
levels. PABPN1 levels are established by a feed-forward loop combining at
least regulation of mRNA stability and protein turnover. PABPN1 protein
accumulation is regulated by the ubiquitin proteasome system (UPS),
including ARIH2 E3-ligase. An aging-associated distortion of the UPS
causes impairment of PABPN1 protein turnover affecting its mRNA stability
and genes of the UPS, including ARIH2 E3-ligase. In turn, PABPN1 mRNA
levels, which are self-regulated, also decrease with aging. However, the
molecular factors regulating PABPN1 mRNA stability are unknown as yet.
In OPMD and in aging, reduced levels of PABPN1 eventually cause
genome-wide changes in gene expression.
mRNA dysregulation of the UPS was found to be the most consis-
tent dysregulated cellular system in OPMD (Anvar et al., 2011; de
Klerk et al., 2012). Although a mechanistic model for regulation
of PABPN1 levels in aging and muscle disease calls for additional
research, the current literature suggests that changes in PABPN1
levels in muscles are regulated by both mRNA stability and pro-
tein turnover and that these machineries are specifically affected
in OPMD (Figure 1). Regulators of PABPN1 mRNA stability and
protein turnover should be identified in future studies.
WHY SPECIFIC MUSCLES SEEM TO BE MORE AFFECTED
THAN OTHER MUSCLES?
In OPMD, the ocular and pharyngeal muscles are initially the most
commonly affected; however, with progression of the disease, more
skeletal muscles are affected. These muscles are also often affected
in otherwise healthy elderly. Most skeletal muscles are weakened
during aging; however, it is unclear whether aging-associated mus-
cle weakness is programed, concerning initially affected muscles
and progression. Relevant to OPMD, dysphagia, resulting from
weakness of pharyngeal muscles, and eyelid ptosis, resulting from
weakness of the levator palpebrae muscle, is highly common in
the elderly (Salvi et al., 2006; Fea et al., 2013; Iida et al., 2013).
In contrast to the otherwise healthy population, in OPMD, symp-
toms start at an earlier age and seem more severe, possibly due
to faster progression. Eyelid ptosis can also be caused by rare
multiple mitochondrial DNA deletion syndromes, including pro-
gressive external ophthalmoplegia (PEO) (Van Goethem et al.,
2003). Increased mitochondrial deletions were found in the extra-
ocular muscles compared to other muscles and are aging associated
(Yu-Wai-Man et al., 2010), indicating a prominent role for mito-
chondrial activity in ocular muscles during aging. A decrease in
mitochondrial activity was reported in a mouse model for OPMD
(Trollet et al., 2010) and in a muscle cell model with PABPN1
downregulation (Anvar et al., 2013). These studies suggest that in
OPMD, mitochondrial dysfunction may contribute to the muscle
weakness and future studies should explore a role for PAPBN1
in the regulation of mitochondrial genes and mitochondrial and
metabolic cellular functionality.
Dysphagia in the elderly is determined by age-associated
anatomical changes in the neck and throat, underpinning the swal-
lowing function in otherwise healthy elderly (Ney et al., 2009).
Furthermore, dysphagia is also common in different age-related
diseases including NM disorders (Schindler and Kelly, 2002). Dys-
phagia in the otherwise healthy elderly manifests by a less efficient
passage of food to the esophagus due to changes in swallowing
pressures of the upper esophageal sphincter and delayed muscle
movements (Yokoyama et al., 2000). Symptoms are suggested to
be associated with an increase in muscle atrophy and a decrease in
muscle strength of the pharyngeal muscles (Feng et al., 2013).
Although it is not clear why ocular and pharyngeal muscles are
initially affected in OPMD, the ocular and pharyngeal muscles are
constantly, and often unconsciously, routinely used in daily life.
Interestingly, PABPN1 levels in mice pharyngeal muscle are lower
compared with other skeletal muscles (Apponi et al., 2013). This
suggests that this muscle could be more susceptible to a further
decrease in PABPN1 levels. However, functional studies, especially
in human beings, would lead to conclusive answers.
WHY SYMPTOMS INITIATE FROMMIDLIFE ONWARD AND
DOES OPMD REPRESENT ACCELERATED MUSCLE AGING?
Muscle aging (sarcopenia) is marked, among others, by a decrease
in muscle mass (atrophy), an increase in fat infiltration and inflam-
mation leading to a decrease in muscle strength and physical
performance (Cruz-Jentoft et al.,2010). In the A17.1 mouse model,
muscle atrophy appears already from 12 weeks of age (24–month-
old mice are considered as aged) and is complemented by expres-
sion dysregulation of known muscle atrophy genes such as Murf1
and Atrogin-1 (Trollet et al., 2010). Muscle atrophy in this mouse
model is prominent in the fast glycolytic (type IIX/IIB) fibers,
whereas the slow oxidative (type I) and fast oxidative (type IIA)
fibers seem to be spared (Trollet et al., 2010). Although it is widely
accepted that aged muscles of rodents are enriched in slow (type
I) fibers compared to fast (type II) fibers, in aging human muscles,
the literature concerning this fiber-type switch is not conclusive
(Purves-Smith et al., 2014). Therefore, the implications of the
muscle fiber-type switch for OPMD patients are unsettled. Stud-
ies in additional models are necessary in order to reveal whether
reduced PABPN1 levels induce muscle atrophy and muscle fiber-
type switch. Muscle aging can also be non-invasively quantified
from magnetic resonance imaging (MRI) including muscle cross-
sectional surface area, fatty infiltration (Fischmann et al., 2012;
Willis et al., 2013), and inflammation (Eshed et al., 2007). These
measures can be considered as approximations of muscular qual-
ity. With these measures, progressive muscular atrophy in OPMD
was documented (Fischmann et al., 2012).
Although OPMD is often grouped within the muscular dystro-
phies, our studies of RNA expression profiles in OPMD muscles
and OPMD models revealed higher similarities with muscles from
the elderly rather than with muscular dystrophies or myopathies
(Anvar et al., 2013), suggesting similar molecular signatures. Over-
lapping dysregulated genes were found for the mitochondria, the
UPS, DNA repair, TGF-β signaling, and sarcomeric genes (Anvar
et al., 2013). However, functional studies should investigate a
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FIGURE 2 | A schematic working model for the aging-associated
decline of muscle strength and PABPN1 in OPMD (A) and healthy
controls (B). In skeletal muscles, a decline in PABPN1 levels starts from
midlife onward in both OPMD and healthy controls. The onset of decline
from midlife onward is caused by secondary age-associated effectors,
which mostly are unknown. Eventually, below a critical PABPN1 level,
muscle weakness symptoms are manifested. This process is accelerated in
OPMD due to aggregation of expanded PABPN1, which further depletes
levels of functional PABPN1. In other tissues, however, levels of PABPN1
are higher and a possible age-related decline of PABPN1 does not reach the
critical level for a functional impact.
role for additional aging-associated pathways. For example, the
autophagy system has also been found to have an imperative
regulatory role in many age-associated diseases, in healthy aging
(Schneider and Cuervo, 2014), and in muscle atrophy (Bonaldo
and Sandri, 2013). As PABPN1 can shuttle between the nucleus
and the cytoplasm (Abu-Baker et al., 2005; Benoit et al., 2005), it
should be investigated whether PABPN1 is also regulated by the
autophagy system. Moreover, genes of the autophagy system could
be regulated by PABPN1 (Anvar et al., 2013). More interestingly,
age-associated changes in a cross-sectional data revealed a faster
change in expression level for a subset of genes, among which many
are known as aging genes, muscle-specific sarcomeric genes, and
PABPN1 (Anvar et al., 2013). This suggests that muscle weakness
in OPMD could represent accelerated muscular aging, and thus,
OPMD muscles could be a paradigm for otherwise healthy muscle
aging (Figure 2).
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